---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-22-000179"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:35:52.099662+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Humacyte reports Q3 2022 net loss $25.3M, cash $171.7M, BLA filing for vascular trauma mid 2023

## Summary
- Cash $171.7M at Sep 30, 2022; net loss $25.3M for Q3; cash runway through 2024.
- BLA filing for HAV in vascular trauma anticipated mid 2023; 56 patients enrolled in V005 trial as of Oct 31.
- Phase 3 AV access trial nearing completion (227 of 240 enrolled); top-line results 1 yr after enrollment.
- Appointed Dr. Cindy Cao as Chief Regulatory Officer and Lt. Gen. C. Bruce Green to Board.
- Partnered with Diabetes Research Institute for Biovascular Pancreas program in type 1 diabetes.

## SEC filing metadata
- accession: 0001818382-22-000179
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838222000179/0001818382-22-000179-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838222000179/huma-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-22-000179
- JSON: https://secwatch.observer/filing/0001818382-22-000179.json
- Plain text: https://secwatch.observer/filing/0001818382-22-000179.txt

## Key facts
- Earnings Releases
  Humacyte, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Humacyte, Inc. issued a press release regarding its financial results for its fiscal third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818382/000181838222000179/0001818382-22-000179-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.